| Abstract: |
A combination of antiviral therapies that target different sites in the human immunodeficiency virus type 1 (HIV-1) replicative cycle may be necessary for optimal treatment of HIV-1 infections. We evaluated the interactions of a soluble virus receptor (recombinant soluble CD4 or rsT4) and a reverse transcriptase inhibitor (azidothymidine, AZT) against HIV-1 replication in vitro. A variety of cell types was studied including peripheral blood mononuclear cells, a CD4-positive T-cell line, and a CD4-positive human monocyte cell line. The combination of rsT4 and AZT inhibited HIV-1 synergistically over a broad range of drug concentrations and multiplicities of infection in several different HIV-1 replication assays. Drug interactions were evaluated by the median-effect principle and the isobolo- gram technique using a computer analysis. In all of the cell types tested, combinations of rsT4 and AZT were synergistic in vitro, without additive cytotoxicity. © 1989 by The University of Chicago. All Rights Reserved. |
| Keywords: |
drug potentiation; immunofluorescence; in vitro study; dose-response relationship, drug; virus receptor; receptors, virus; drug synergism; antigen presentation; mononuclear cell; cell culture; recombinant proteins; cd4 antigen; virus replication; clone cells; human immunodeficiency virus 1; cytopathogenic effect; hiv-1; zidovudine; antigens, differentiation, t-lymphocyte; rna directed dna polymerase inhibitor; human; priority journal; support, u.s. gov't, p.h.s.; receptors, hiv
|
